mFOLFOX6-bevacizumab
Phase 3Monoclonal antibody
mFOLFOX6-bevacizumab is one of 29 biologic programs targeting Metastatic Colorectal Cancer. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
28
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
698 competitors in Metastatic Colorectal Cancer
#DrugCompanyPhaseTrials
1Vectibix
AmgenPhase 3
Braftovi
PfizerPhase 3
Theraplaza
BBiotech Pharmaceutical Co., Ltd.
Phase 3
Fusilev
DDurata Therapeutics International BV (an Affiliate of Actavis, Inc.)
Phase 3
Cosela
PPharmacosmos A/S
Phase 3
Vatalanib
NovartisPhase 3
PF-08634404
PfizerPhase 3
QL1706
Qilu Pharmaceutical Co., Ltd.Phase 3
Brivanib Alaninate
GGynecologic Oncology Group
Phase 3
FOLFOX 2d
SSichuan Baili Pharmaceutical Co., Ltd.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Metastatic Colorectal Cancer1 trial
Multi-Line Therapy Trial in Unresectable Metastatic Colorectal Cancer
Active, not recruiting·GGERCOR - Multidisciplinary Oncology Cooperative Group·Phase 3·NCT01910610·464 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for mFOLFOX6-bevacizumab. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details